Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)

ARDELYX, INC.

2026-Q1 EPS reported -$0.15 revenue$94,473,000

Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.
Cash & investments $238.1M as of Mar 31, 2026; reiterated FY 2026 IBSRELA guidance $410-430M.
IBSRELA Phase 3 CIC trial (ACCEL) enrolling; topline data expected H2 2027.
Appointed Rajani Dinavahi, M.D. as CMO and Felecia Ettenberg, Esq. as CLO in April.
Refinanced debt with SLR Investment Corp for better terms; Morgan Stanley advised.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported quarter ended March 31, 2026 results: revenue Total product revenue for the quarter ended March 31, 2026 was $93.4 million, net income Net loss for the quarter ended March 31, 2026 was $37.6 million, EPS $(0.15) per share.

Period: quarter ended March 31, 2026
Revenue: Total product revenue for the quarter ended March 31, 2026 was $93.4 million
Net income: Net loss for the quarter ended March 31, 2026 was $37.6 million
EPS: $(0.15) per share
Result: reported results

Exact text from the filing

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001437402-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.